By Ben Hirschler LONDON (Reuters) – New global guidelines on the treatment of heart failure strongly endorse the use of Novartis’ Entresto, boosting the prospects for a drug that has struggled to gain traction since its launch last year. U.S. and European heart experts gave the highest “class 1” recommendation to Entresto for use in patients with heart failure, a debilitating condition in which the heart is unable to pump enough blood around the body. The guidance in the key U.S. market says that Entresto should replace two older types of drugs known as ACE inhibitors and ARBs in heart failure patients who have adequate blood pressure and tolerance to standard drugs.
Go here to read the rest:
Struggling Novartis heart drug boosted by new medical guidelines
